OWLiver®

The advanced lipoprotein test requires 0.2 ml of serum for the determination of a lipidomic fingerprint and the measurement of 40 metabolites from High Performance Liquid Chromatography with Mass Spectrometry (UPLC-MS).

The OWLiver^® medical software algorithm panel generates a report reflecting a complete characterization of metabolites reflecting the amount of liver fat, inflammation, and fiber deposition, for a final OWLiver^® score. The determination value indicates the probability of approximation of the patient’s liver status to a healthy liver, steatotic, with steatohepatitis, or with steatohepatitis and significant-advanced fibrosis (≥F2).

1. Barr J, Caballería J, Martínez-Arranz I, Domínguez-Díez A, Alonso C, Muntané J, et al. Obesity-dependent metabolic signatures associated with nonalcoholic fatty liver disease progression. J Proteome Res. 2012;11(4):2521 -32.2.
2. Mayo R, Crespo J, Martínez‐Arranz I, Banales JM, Arias M, Mincholé I, et al. Metabolomic‐based noninvasive serum test to diagnose nonalcoholic steatohepatitis: Results from discovery and validation cohorts. Hepatol Commun. 2018;2(7):807 -20.
3. Noureddin M, Mayo R, Martínez-Arranz I, Mincholé I, Cusi K, Bril F, et al. Serum-based Metabolomics Advanced StEatohepatitis Fibrosis Score (MASEF) for the non- invasive identification of patients with non-alcoholic steatohepatitis with significant fibrosis. J Hepatol. 2020; 73(1):S136
4. Ortiz P, Mincholé I, Mayo R, Martínez-Arranz I, Banales JM, Arrese M, et al. Serum metabolomics-based steatohepatitis score for the non-invasive identification of patients with non-alcoholic steatohepatitis (NASH) in multiethnic, including type 2 diabetes mellitus population. J Hepatol. 2021;75(2): S574

For more information: owliver@labrubio.com

Developed by: Rubió Metabolomics, S.L.U.

Ownership: Rubió Metabolomics, S.L.U.

Marketed and distributed by Laboratorios Rubió as a local and international representative.